CML Treatments

Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic ...
Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML)

CORRECT(1/12): NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel
CORRECT(1/12): NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel

CORRECT: NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel
CORRECT: NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel

Press Release
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in ...

When, And How, To Ask For A Second Medical Opinion
When faced with a major medical decision, it can be difficult for patients to determine when it's appropriate to seek a second opinion. Asking another doctor can help catch misdiagnoses or prevent unnecessary treatments, but they can also be a waste of time and resources.

BB Biotech closes 2011 with a positive performance and confirms upward trend
Portfolio of BB Biotech AG as of December 31, 2011 Despite strong headwinds from the financial markets, BB Biotech achieved a positive performance of 5.6% in CHF and 8.6% in EUR (incl. dividends) in 2011 ...

Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011
Fourth quarter sales rose 5% while core[1] operating income grew 17% in constant currencies (cc); full year sales up 12% cc and core operating income up 16% cc Net sales increased 4% (+5% cc) to USD 14.8 ...

Dr. Brian Druker honored with Japan Prize
( Oregon Health & Science University ) Oregon Health & Science University congratulates Brian J. Druker, M.D., who has been awarded the 2012 Japan Prize in Healthcare and Medical Technology for his pioneering role in targeted cancer drugs. The Japan Prize is considered one of the world's most prestigious awards in science and technology. Druker's research proved it was possible to shut down ...

‘The C-word’ doesn’t slow this family
tbritt@lakecityreporter.com

Bestellen Sie den kostenlosen Newsletter von 4investors:
BB BIOTECH AG / BB Biotech closes 2011 with a positive performance and confirms upward trend . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.